Arrivent's EGFR TKI pivotal readout

Kaveri describes Arrivent's third-generation EGFR inhibitor ferminertinib and its event-driven pivotal data expected in 2026.

Play episode from 04:24

Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!